Novo Nordisk CEO, Mike Doustdar, addressed concerns about the impact of price reductions on the company's established business. He emphasized the robust initial demand for the Wegovy weight-loss pill. The launch has been remarkably successful, with 170,000 patients in the first four weeks, positioning it as one of the most successful pharmaceutical product introductions ever.

This rapid uptake of Wegovy is a significant positive for Novo Nordisk, especially as the company navigates changes in its legacy business. The market for weight-loss drugs is booming, with considerable investment from both pharmaceutical companies and investors. Competition is intensifying, but early demand suggests a strong market position for Wegovy.

The success of Wegovy is critical for Novo Nordisk's growth strategy. It is competing with other weight loss drugs like Ozempic and Mounjaro. Investors will be watching closely to see if Novo Nordisk can sustain this initial momentum and manage production to meet the high demand.

Looking ahead, the company's ability to maintain supply and manage potential pricing pressures will be key. The market will also assess the long-term impact of Wegovy on Novo Nordisk's overall financial performance and its competitive standing in this rapidly expanding therapeutic area.